Trials / Completed
CompletedNCT04725292
Rare Benign Lesion of Peins
Pseudoepitheliomatous Hyperplasia of the Penis a Very Rare Disease in Egypt
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Assiut University · Academic / Other
- Sex
- Male
- Age
- 35 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
PEKMB was first named and described by Lortat-Jacob \& Civatte in 1961 and by Bart \& Kopf later. This rare condition is mostly reported in elderly males. The keratotic scales is usually micaceous and resembles psoriasis. Most patients are above 50 years of age and are circumcised later in life, but also reported in younger age group. This mica like scales contains keratin which gets dissolved in 10% potassium hydroxide solution. Disease progression may lead to phimosis. Differential diagnosis of this disease entity include moniliasis, wart, psoriasis ,penile horn, circinate balanitis, erythroplasia of Queyrat, squamous cell epithelioma and verrucous carcinoma. It is primarily a benign entity, it is capable of invasiveness. Bart and Kopf considered it to be in intermediate stage between benign hyperplasia and squamous cell carcinoma. However, the histological spectrum can range from hypertrophic-hyperplastic penile dystrophy to verrucous carcinoma. Fibro sarcoma has been reported developing in a same patient. Etiology is unclear. Despite search for a viral agent, Human Papilloma Virus (HPV) has not been demonstrated and its role in pathogenesis or its transformation to verrucous carcinoma has been proved. The treatment of PEKMB should be conservative when there is no histological evidence of malignancy. All such patients should be followed up. Treatment choices include potent topical steroids, topical 5% 5-flurouracil cream1, 2, cryotherapy, radiotherapy and shaving biopsy plus electro coagulation. When frank malignancy is observed, excision with wide margin is the rule.
Conditions
Timeline
- Start date
- 2021-01-12
- Primary completion
- 2021-01-12
- Completion
- 2021-01-12
- First posted
- 2021-01-26
- Last updated
- 2021-01-26
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04725292. Inclusion in this directory is not an endorsement.